Littlefield Corp (LTFD): Rawnoc, q4 and q2 is generally there bes...

Rawnoc, q4 and q2 is generally there best

SSKILLZ1 · 2006-09-20T15:07:55.2800000Z

Rawnoc, q4 and q2 is generally there best quarters. Hope this helps. All is just my opinion, and I could always be wrong though.

Play Episode

5min

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Kodal Minerals nears completion at Bougouni Lithium project, prepares for exports

Kodal Minerals PLC (AIM:KOD) CEO Bernard Aylward takes Proactive's Stephen Gunnion through the company's latest update on its Bougouni lithium project in Mali, where construction is nearly complete and preparations for export are underway. Aylward shared that the optimisation and ramp-up phase of the processing plant has been going well, with over 11,000 tonnes of lithium concentrate already stockpiled and ready for export. "We've been making some adjustments as we go through this process and some improvements to the feed into the crusher... achieving a good product," he said. He noted that the company expects to reach nameplate capacity within the next couple of months, pending a final review and approval by the construction team. Kodal is also progressing steadily on the mining front, with a good run-of-mine (ROM) stockpile in place. The interview highlighted that the mining license transfer process is still ongoing, though Kodal has completed all compliance steps and is now awaiting sign-off from the Committee of Ministers and the President of Mali. Once this is finalised, the company will move forward with export permits and begin shipping product. Visit Proactive’s YouTube channel for more company updates. Don’t forget to like this video, subscribe, and turn on notifications to stay up to date. #KodalMinerals #Lithium #BougouniProject #MiningNews #BatteryMetals #MaliMining #ResourceDevelopment #LithiumProduction #MineralExploration #CriticalMinerals

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

Tolu Minerals CEO reveals 8 new targets at Mt Pence and talks initial gold production at Tolukuma

Tolu Minerals Ltd CEO Iain Macpherson talked with Proactive about the company’s initial gold production at the Tolukuma Gold Mine in Papua New Guinea. While not commercial output yet, Macpherson explained that gold from commissioning demonstrates proof of concept and marks the start of larger-scale activity. The company is leveraging existing infrastructure valued at around AU$500 million, with a strategy focused on addressing previous cost pressures that led to mine closure. “The mine shut down, not because the resource ran out... but because they were faced with severe cost pressures,” Macpherson said, citing diesel dependence and lack of road access. Macpherson highlighted Tolu’s capital program and extensive exploration footprint across the broader Tolukuma structure. He detailed the utility of airborne magnetotelluric (MT) surveys, which provide deep, three-dimensional geophysical data. “It gives you a very good three-dimensional picture... and enhances target generation,” he said, noting this method’s success in similar geologies globally. The company also discussed its Mt Penck project on New Britain Island, revealing the identification of eight new porphyry targets based on the MT survey. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future content. #ToluMinerals #GoldMining #ASXTOK #PapuaNewGuinea #Tolukuma #GoldExploration #MiningStocks #PorphyryTargets #MTsurvey #JuniorMining #GoldProduction #InvestorUpdates #MiningNews

Followers	295
Posts	89265
Boards Moderated	65
Alias Born	02/06/2005

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free